BioSpace News Archive

Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the first person has been dosed under Gritstone’s “CORAL” program with its candidate COVID-19 vaccine in a Phase 1 study.

Three out of four Getinge employees who have worked from home during the COVID-19 pandemic believe that the setup has improved their productivity as well as their work-life harmony.

Up to 400 million doses of the Company’s single-shot vaccine candidate will be made available to African Union member states

Genestack Ltd. announced that its flagship multi-omics data catalog, curation and integrative search product, Omics Data Manager, has been licensed and implemented by the Dutch vegetable breeding firm Bejo.

The Menarini Group announced today that it has entered into an exclusive license agreement for the development and commercialization of ELZONRIS® (tagraxofusp) in the territory of Japan with Nippon Shinyaku Co., Ltd. ELZONRIS is approved for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) by the U.S. Food and Drug Administration and the European Medicines Agency.

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, announced that management will host a conference call and webcast today at 8am ET to discuss topline results from the Phase 3 clinical trial of lenzilumab in patients hospitalized with COVID-19.

First and only tongue-delivered neuromodulation therapy provides new treatment option for U.S. patients living with gait deficit due to symptoms from multiple sclerosis

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported interim data from the Company’s ongoing, open label clinical trial of CDX-0159 in patients with antihistamine refractory cold contact urticaria (ColdU) and symptomatic dermographism (SD), the two most common forms of chronic inducible urticaria (CIndU)

LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, is pleased to announce that Amy C. Moore, PhD, will join the Foundation as its first Vice President of Global Engagement and Patient Partnerships.

The KD Pharma Group has acquired the manufacturing assets of the former Rohner AG. The assets give KD Pharma access to new complementary technologies that will allow the company to further expand its pharmaceutical contract manufacturing (“CDMO”) business.